Physician profile
Matthew A Meyer
NPI 1629204383
$4,597.98
in general payments reported to CMS, 2019-2025
49 companies · $851 in 2025
The $851 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $788 · 2020: $407 · 2021: $386 · 2022: $536 · 2023: $876 · 2024: $755 · 2025: $851.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,481.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,481.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,058.27 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $347.41 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $328.20 | 2021-2025 | Ingrezza, Ongentys |
| Vanda Pharmaceuticals INC. | $310.82 | 2025 | Ponvory |
| Novo Nordisk INC | $270.09 | 2019-2022 | |
| Ucb, INC. | $231.70 | 2019-2025 | Briviact, Rystiggo |
| Eisai INC. | $145.97 | 2023-2025 | |
| Lilly USA, LLC | $141.19 | 2019-2024 | Emgality, Reyvow |
| Amgen INC. | $107.74 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $104.59 | 2019-2025 | Austedo Xr, Austedo Xr |
| Livanova USA, INC. | $102.46 | 2019-2023 | Vns Therapy Sentiva Model 1000 Generator |
| Emd Serono, INC. | $99.71 | 2019-2023 | Mavenclad |
| Genzyme Corporation | $93.32 | 2019-2020 | |
| Radius Health, INC. | $91.12 | 2020-2024 | Tymlos |
| Catalyst Pharmaceuticals, INC. | $81.45 | 2023 | Fycompa |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.